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Nuclear factor-erythroid 2-related factor 2 (NRF2) is a pleiotropic transcription factor 
that has neuroprotective and anti-inflammatory effects, regulating more than 250 genes. 
As NRF2, cannabinoid receptor type 2 (CB2) is also implicated in the preservation of 
neurons against glia-driven inflammation. To this concern, little is known about the 
regulation pathways implicated in CB2 receptor expression. In this study, we analyze 
whether NRF2 could modulate the transcription of CB2 in neuronal and microglial cells. 
Bioinformatics analysis revealed an antioxidant response element (ARE) in the promoter 
sequence of the CB2 receptor gene (CNR2). Further analysis by chemical and genetic 
manipulations of this transcription factor demonstrated that NRF2 is not able to modulate 
the expression of CB2 in neurons. On the other hand, at the level of microglia, the 
expression of CB2 is NRF2-dependent. These results are related to the differential levels 
of expression of both genes regarding the brain cell type. Since modulation of CB2 
receptor signaling may represent a promising therapeutic target with minimal 
psychotropic effects that can be used to modulate endocannabinoid-based therapeutic 
approaches and to reduce neurodegeneration, our findings will contribute to disclose the 















































































In recent years, the transcription factor Nuclear Factor erythroid-derived 2-like 2 
(herein referred as NRF2, encoded by NFE2L2 gene) has emerged as an essential factor 
in modulating the expression of genes involved in a broad spectrum of cellular functions. 
Although NRF2 was originally described as the master regulator of redox homeostasis 
(Itoh et al. 1997; Itoh et al. 1995), its role in mechanisms involved in neuroinflammation, 
proteasome/autophagy, DNA repair, apoptosis, iron and heme metabolism as well as 
phase I, II, and III drug/xenobiotic metabolism has now been described (Hayes and 
Dinkova-Kostova 2014; Schmidlin et al. 2019). In basal conditions, there are low levels 
of NRF2 due to the action of an E3 ubiquitin ligase complex containing a substrate 
adaptor protein, Kelch-like ECH-associated protein 1 (KEAP1), that binds to and 
negatively regulates NRF2 (Itoh et al. 1999). Oxidative or electrophilic stress induces 
NRF2 signaling through modifications of key cysteine residues in KEAP1 that induce 
conformational changes in the binding of NRF2-KEAP1 that avoids the degradation of 
NRF2. This allows the accumulation of newly synthesized NRF2, which can then 
translocate to the nucleus and bind to the antioxidant response element (ARE) sequence 
in the promoter regions of NRF2-dependent genes, and recruit transcriptional machinery 
(Itoh et al. 1997). 
Because NRF2 is able to regulate the expression of more than 250 genes, its 
capacity for action is very broad. At the level of the central nervous system (CNS), it has 
been described that the activation of NRF2 has beneficial effects against the main 
hallmarks of neurodegeneration. Pharmacological activation of NRF2 induces 
proteasome and autophagy enhancing the degradation of protein aggregates (Lastres-
Becker et al. 2016; Pajares et al. 2016; Rojo et al. 2017), has anti-inflammatory effects 




































































oxidative stress (Lastres-Becker 2017; Cuadrado et al. 2018b). On the other hand, 
deficiency in NRF2 worsens all these parameters exacerbating the neurodegenerative 
process. Therefore, modulation of NRF2 activity has the potential to alter 
neurodegenerative disease course (Burnside and Hardingham 2017; Cuadrado et al. 
2018a; Lastres-Becker 2017; Lastres-Becker et al. 2016). 
Like the NRF2 pathway, the endocannabinoid system has emerged as an important 
neuromodulation system for many brain functions (Zanettini et al. 2011). The 
endocannabinoid system consists of cannabinoid receptors type 1 and 2 (CB1 and CB2), 
their endogenous ligands, and the enzymes for synthesis and metabolism of the 
endocannabinoids (Di Marzo 2018). The CB2 receptor, a seven-transmembrane and G 
protein-coupled receptor, is generally expressed in immune tissues and cells but is also 
present at low levels in neuronal and non-neuronal (quiescent microglia, for example) 
brain cells (Navarro et al. 2016). As NRF2, CB2 receptor activation has exhibited great 
potential as anti-oxidative stress and anti-inflammation in various disease models (Di 
Marzo 2018) and its potential as a therapeutic target is being investigated. An important 
aspect in this research is the fact that, despite the modest expression of CB2 receptors in 
glial elements in normal conditions of the CNS, they experience a notable up-regulation 
in response to different neurotoxic (e.g. proinflammatory, oxidative, traumatic, 
infectious) insults. This up-regulation involves the induction of CB2 receptor gene 
expression, although little is known about the elements (transcription factors) involved in 
this response. In this respect, it has been described that the promoter region of human 
CNR2 (CB2 receptor gene) contains several boxes with a transcription binding site for 
stress response such as AP-1 or AP-4 (activator protein 1 or 4), HSF (heat shock factor) 
and STRE (stress response element), depending on the isoform (Onaivi et al. 2012). As 




































































actions, this evidence prompted us to investigate whether NRF2 could be one of the key 
transcription factors implicated in the expression of CB2.  
 
MATERIAL AND METHODS 
Bioinformatics analysis. A putative antioxidant response element (ARE) in CNR2 
gene promoter was identified in The Encyclopedia of DNA Elements at UCSC 
(ENCODE) (http://genome.ucsc.edu) for the human genome (Feb. 2009), taking as 
reference the available information from chromatin immunoprecipitation (ChIP) of ARE-
binding factors MAFK and BACH1. The putative MAFK was localized in a 280-base 
pair long DNase-sensitive and H3K27Ac-rich region, i.e., most likely regulatory 
promoter regions. In addition, a frequency matrix of the consensus ARE sequence based 
on the JASPAR database (http://jaspar.genereg.net) was converted to a position-specific 
scoring matrix (PSSM) by turning the frequencies into scores through the log(2) [odd-
ratio (odd ratio: observed frequency/expected frequency)]. One unit was added to each 
frequency to avoid log(0). Then a script was generated with the Python 3.4 program to 
scan the promoter sequences with candidate AREs retrieved from ENCODE with the 
PSSM. The max score was calculated by adding the independent scores for each of the 
11 base pairs of the consensus ARE sequence with the PSSM. The relative score (score 
relative) was calculated from this max score (score of the sequence max) as: score relative 
= (score of the sequence max – score min possible)/(score max possible – score min possible). The min 
possible score (score min possible) is calculated as the lowest possible number obtained for a 
sequence from the PSSM and the max possible score (score max possible) is the highest 
possible score that can be obtained. We considered putative ARE sequences those with a 
score relative over 80%, which is a commonly used threshold for the computational 




































































Cell culture. Primary microglia were prepared from neonatal (P0-P2) mouse 
cortex from Nfe2l2+/+ and Nfe2l2-/- mice (obtained from colonies of Nfe2l2-/- mice and 
Nfe2l2+/+ littermates established from founders kindly provided by Dr. Masayuki 
Yamamoto (Tohoku University Graduate School of Medicine, Sendai, Japan)) (Itoh et al. 
1997) and grown and isolated as described in (Lastres-Becker et al. 2014). Briefly, 
neonatal (P0-P2) mouse cortex was mechanically dissociated and the cells were seeded 
onto 75 cm2 flasks in Dulbecco's Modified Eagle Medium:F12 (DMEM:F12) 
supplemented with 10% fetal calf serum (FCS) and penicillin/streptomycin. After 2 
weeks in culture, flasks were trypsinized and separated using CD11b MicroBeads for 
magnetic cell sorting (MACS Miltenyi Biotec, Germany). Microglial cultures were at 
least 99% pure, as judged by immunocytochemical criteria. Medium was changed to 
DMEM:F12 serum-free without antibiotics 16 h before treatment. Immortalized 
microglial cell line (IMG), isolated from the brains of adult mice, was purchased from 
Kerafast Inc. HT22 mouse hippocampal neuronal cell line was obtained from Dr. Ana 
Pérez laboratory (Biomedical Research Institute, Madrid, Spain). IMG and HT22 cells 
were grown in DMEM supplemented with 10% fetal bovine serum, 1% 
penicillin/streptomycin and 2 mM L-glutamine, in 5% CO2 at 37ºC, 50 % relative 
humidity. Primary neuronal cultures were prepared from the cerebral cortex of 18-day-
old Wistar rat embryos (E18), both genders being indistinctly used. Dissected cerebral 
cortices were mechanically dissociated in culture medium (Minimum Essential Medium, 
Life Technologies) supplemented with 22.2 mM glucose, 0.1 mM glutamax, 5% fetal 
bovine serum, 5% donor horse serum, 100 U/ml penicillin and 100 µg/ml streptomycin 
similarly as described before (Choi et al. 1987). The cell suspension was seeded at a 
density of 1x106 cells/ml in the same medium using plates previously treated with poly-




































































37 °C. After 4 h, culture medium was changed to Neurobasal (Life Technologies) 
containing B27 serum-free supplement (Life Technologies), 2 mM glutamax (Life 
Technologies), 100 U/ml penicillin and 100 µg/ml streptomycin. Growth continued until 
DIV 7, when medium was changed to fresh Neurobasal medium completed as before but 
omitting glutamax. Experimental treatments took place after 12 DIVs by adding reactives 
directly to the growth medium. Medium was changed to serum-free DMEM without 
antibiotics 16 h before treatments for IMG and HT22 cells. Dimethyl fumarate (DMF) 
was obtained from Sigma-Aldrich (Cat number 242926) and used at 20 M. 
Analysis of mRNA levels by quantitative real-time PCR. Total RNA extraction, 
reverse transcription and quantitative polymerase chain reaction (qPCR) were done as 
detailed in previous articles (Lastres-Becker et al. 2014). Primer sequences are shown in 
Supplementary Table S1. Data analysis was based on the ΔΔCT method with 
normalization of the raw data to housekeeping genes (Applied Biosystems). All PCRs 
were performed in triplicates. 
Immunoblotting. Whole cell lysates were prepared in RIPA-Buffer (25 mM Tris-
HCl pH 7.6, 150 mM NaCl, 1 mM EGTA, 1% Igepal, 1% sodium deoxycholate, 0.1 % 
SDS, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF, 1 μg/ml aprotinin, 1 μg/ml leupeptin and 
1 μg/ml pepstatin). Whole cell lysates, cytosolic and nuclear fractions containing 25 μg 
of whole proteins from IMG-treated cells were loaded for SDS-PAGE electrophoresis. 
Immunoblots were performed as described in (Cuadrado et al. 2014). The primary 
antibodies used are described in Supplementary Table S2. 
NRF2 overexpression. HT22 cells were seeded on 6-well plates (300,000 
cell/well) and transfected with an NFE2L2 expression plasmid (8 g) that lacks the high 
affinity binding site for KEAP1 and contains a V5 tag (NRF2ΔETGE-V5) (McMahon et al. 




































































Hospital and Medical School, University of Dundee) or pcDNA3.1/V5HisB. After 24 h 
from transfection with Lipofectamine 2000 Reagent (Invitrogen Life Technologies, Cat 
number 116668–019), cells were lysed for analysis of mRNA levels by quantitative real-
time PCR. 
Production of lentiviral stocks and infection of HT22 cells. Recombinant lentiviral 
stocks were produced in HEK293T cells by cotransfecting shCtrl or shNRF2 
(shCLN_NM_010902, MISSION shRNA, Sigma) (Robledinos-Anton et al. 2017), 6 μg 
of envelope plasmid pMD2.G (Addgene; deposited by Dr. Didier Trono) and 6 μg of 
packaging plasmid pSPAX2 (Addgene; deposited by Dr. Didier Trono), using 
Lipofectamine 2000 Reagent (Invitrogen Life Technologies). After 12 h at 37 °C, the 
medium was replaced with fresh DMEM containing 10% fetal bovine serum. Virus 
particles were harvested at 24 h and 48 h post-transfection. HT22 cells were incubated in 
the presence of 2 µg/ml polybrene (Sigma-Aldrich, TR-1003-G) with the lentivirus 
during 24 h, and then selected with Puromycin (5 µg/mL) for 48 h. mRNA was extracted 
7 days after lentiviral transduction.  
RNA-Seq of cell types isolated from mouse. Differential distribution of the mRNA 
for Cnr2 and Nfe2l2 in the mouse brain were obtained from the Brain-RNAseq database. 
For details see Ref. (Zhang et al. 2014). 
Statistical analyses. Data are presented as mean ± SEM. To determine the 
statistical test to be used, we employed GraphPad Instat 3, which includes the analysis of 
the data to normal distribution via the Kolmogorov-Smirnov test. In addition, statistical 
assessments of differences between groups were analyzed (GraphPad Prism 5, San Diego, 




































































fulfilled, or by the non-parametric Mann–Whitney test. One and two-way ANOVA with 
post hoc Tukey test were used, as appropriate. 
 
RESULTS 
Identification of putative AREs in the cannabinoid receptor CNR2 gene 
To define comprehensively the role of NFE2L2 in the transcriptional regulation 
of the CB2 receptor, we searched the Encyclopedia of DNA Elements at UCSC 
(ENCODE) (An integrated encyclopedia of DNA elements in the human genome  2012) 
of the human genome (Feb. 2009) for CNR2 with putative AREs (Figure 1A). The 
ENCODE database gathers experimental data from chromatin immunoprecipitation 
(ChIP) analysis of ARE-binding transcription factors MAFF, MAFK, and BACH1, 
although NFE2L2 is not analyzed. As shown in Figure 1B, the binding site was located 
at histone acetylated and DNase-sensitive regions in the CNR2 gene. Then, we used 
Python-based bioinformatics analysis to scan this binding region for the consensus ARE 
as established in the JASPAR database (Mathelier et al. 2014). We detected one putative 
ARE in the CNR2 gene with a relative score higher than 80%, a commonly used threshold 
for transcription factor binding-site analysis (Figure 1C) (Andersen et al. 2008; Kwon et 
al. 2012). This putative ARE sequence in the CNR2 promotor region has a high degree of 
similarity with the consensus ARE sequence (Figure 1D) described by (Hirotsu et al. 
2012). 
 
CB2 expression in neurons is not NRF2 dependent 
Recently, it has been described that the CB2 receptor could have distinct roles in 
neuronal and microglial cells (Li and Kim 2017). Therefore, to determine whether the 




































































followed different strategies by chemical and genetic manipulations of this transcription 
factor. First, we employed a pharmacological strategy by using dimethyl fumarate (DMF) 
(20 M), a well-known NRF2 inducer (Cuadrado et al. 2018a; Lastres-Becker et al. 
2016). Hippocampal neuronal cell line HT22 cells were maintained under serum-free 
conditions for 16 h and then treated with DMF and data were collected at different time 
points. NRF2 signaling was activated by DMF treatment (Figure 2 A-C) corroborated by 
the observation that mRNA and protein levels of NRF2, heme oxygenase 1 (HO-1) and 
NAD(P)H dehydrogenase quinone 1 (NQO1) were increased in a time-dependent fashion. 
However, neither mRNA or protein levels of CB2 receptor were modified by DMF 
treatment. Similar results were obtained in primary neuronal cultures, where DMF 
treatment for 4 h increased mRNA levels of Hmox1 but not Cnr2 (Figure 2D). Next, we 
overexpressed NRF2 by using a stable mutant, NRF2ΔETGE-V5, that lacks four residues 
(ETGE) essential for recognition by the E3 ligase complex Cul3/KEAP1. More than 80-
fold of change of Nfe2l2 mRNA expression did not induce any modification of Cnr2 
expression (Figure 2E). Finally, we silenced NRF2 with a lentiviral shRNA vector in the 
hippocampal HT22 cell line. Evidence of NRF2-knockdown was provided by analysis of 
mRNA expression levels, where we observed around 50% of decreased expression of 
Nfe2l2 (Figure 2F). Knockdown of NRF2 did not lead to modifications of Cnr2 mRNA 
expression levels. Taken together these results suggest that NRF2 is not capable of 
modulating the expression of the CB2 receptor at the neuronal level. 
 
NRF2 modulates CB2 expression in microglial cells 
 CB2 receptors are largely found on microglial cells when activated by different 
neurotoxic stimuli, then playing important protective roles against these stimuli, in 




































































targeting the CB2 receptor as a promising treatment for glia-driven inflammation and 
neuronal degeneration (Turcotte et al. 2016). Because NRF2 has an important anti-
inflammatory effect, we wanted to analyze if at the level of microglia NRF2 could 
modulate the expression of the CB2 receptor. As before, we followed different strategies 
based on chemical and genetic manipulations of this transcription factor to determine 
whether NRF2 could modulate CB2 receptor expression in microglial cells. First, we 
treated immortalized microglial cells (IMG) with DMF (20 M). IMG cells were 
maintained under serum-free conditions for 16 h and then treated with DMF and data 
were collected at different time points. We corroborated that NRF2 signaling was 
activated by DMF treatment (Figure 3 A-C) by analyzing the mRNA and protein levels 
of NRF2, HO-1, and NQO1 and we demonstrated that they were increased in a time-
dependent way. Interestingly, treatment with DMF first modulates the protein levels of 
NRF2 by increasing the stability of the protein (4 h and 8 h) and subsequently induces its 
transcriptional expression (24h). In relation to these results, we observed that, at 8 h of 
treatment, increased protein expression of CB2 is delayed to that of NRF2 (Figure 3B-C). 
At the mRNA level, we observed a biphasic effect of DMF: first, it induces a decrease in 
the expression of Cnr2 at 4 h and a subsequent induction at 24 h (Figure 3A). 
 Then, we analyzed Cnr2 mRNA expression levels in primary microglial cells 
obtained from Nfe2l2+/+ and Nfe2l2-/- mice. Our results demonstrated that NRF2-deficient 
microglial cells barely express Cnr2 (approx. 90% of reduced expression) in comparison 
to wild type microglial cells (Figure 3D). In this case, we chose not to transfect microglia, 
since it has been described (and we ourselves have observed) that current transfection 
methodologies provide low transfection efficiency and induce cell death and/or 
inflammatory activation of the microglia. Anyway, the results we have obtained clearly 




































































data become even more relevant when we compare the expression levels of Nfe2l2 and 
Cnr2 in the different brain cell types by RNA-seq obtained from (Zhang et al. 2014) 
(Figure 3E). Figure 3E clearly shows that both genes are co-expressed only at the level 
of the microglia, but not in neurons or astrocytes. 
 
DISCUSSION 
During the last decades, knowledge about the endocannabinoid system has 
increased exponentially, although the CB2 receptor has been less well characterized in 
comparison with the CB1 receptor. However, recently, CB2 receptors have gained 
attention, primarily due to their promising therapeutic potential for treating various 
pathologies while avoiding the adverse psychotropic effects that can accompany CB1 
receptor-based therapies (Dhopeshwarkar and Mackie 2014b), although we cannot ignore 
the possibility of provoking immunosuppression. Therefore, it is very important to know 
the mechanisms involved in CB2 transcriptional regulation. Thus, we have analyzed the 
implication of the transcription factor NRF2 in the expression of CB2 at the level of 
neuronal and microglial cells. We showed for the first time that in the promoter region of 
CB2 there is an ARE sequence and that NRF2 is able to specifically modulate the 
expression of CB2 in microglia (Figures 1 and 3). 
It is interesting to note that the regulation of CB2 by NRF2 only occurs at the 
microglia level, which is the cell type where both genes are most highly expressed in the 
brain (Figure 3E). It is also the type of neural cells in which CB2 receptor expression is 
most significantly elevated after their activation. In addition, this result is even more 
relevant when we analyze the involvement of both NRF2 and CB2 in neuroinflammation 
processes associated with microglia activation. NRF2 has been demonstrated to 




































































(Cuadrado et al. 2018a; Lastres-Becker et al. 2014; Rojo et al. 2018; Rojo et al. 2017; 
Castro-Sánchez et al. 2019) and Parkinson’s disease (Lastres-Becker et al. 2016; Lastres-
Becker et al. 2012; Jazwa et al. 2011; Rojo et al. 2010; Lastres-Becker 2017). NRF2 
modulates redox homeostasis and phagocytosis in microglia and deficiency in this protein 
results in exacerbated inflammatory response (Vilhardt et al. 2017), This indicates that 
NRF2 is implicated in modulating microglial dynamics (Innamorato et al. 2009; Rojo et 
al. 2010) through, at least, its interaction with the transcription factor NF-B (Cuadrado 
et al. 2014), master regulator of inflammation. Lack of NRF2 can magnify NF-κB activity 
primarly increasing cytokine production, whereas NF-B can modulate NRF2 
transcription and activity (NFE2L2 promoter has a B site), having both positive and 
negative effects on the gene expression (Wardyn et al. 2015). Related to CB2, it has been 
observed an up-regulation in reactive microglia in the spinal cord of TDP-43 (A315T) 
transgenic mice, an experimental model of amyotrophic lateral sclerosis (Espejo-Porras 
et al. 2019). CB2 up-regulation has been also observed in the context of amyloid-triggered 
neuroinflammation (Lopez et al. 2018), and glia-driven inflammation in CNS structures 
affected, for example, in Parkinson’s disease (Gomez-Galvez et al. 2016) and 
Huntington’s disease (Sagredo et al. 2009; Palazuelos et al. 2009). Such responses have 
been also found in post-mortem tissues from patients affected by these diseases (Jordan 
and Xi 2019). However, it is still unknown what is the molecular mechanism by which 
CB2 activation has anti-inflammatory effects (Wu et al. 2017; Cakir et al. 2019). One 
possibility is that it acts as an inhibitor of the control of proinflammatory cytokines and, 
as NRF2, promotes the shift from M1 to M2 phenotypes. It has been described that 
peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α) may mediate 
CB2 receptor agonist AM1241-induced anti-inflammation in microglial cells, and the 




































































et al. 2018). Therefore, the fact that NRF2 is able to induce the expression of CB2 in 
microglia could shed light on the signaling pathways involved in the anti-inflammatory 
processes. In addition, the induction of CB2 expression at the microglial level would be a 
powerful therapeutic target to treat microgliosis associated with pathologies (Navarro et 
al. 2016; Soethoudt et al. 2017). 
Although in principle it has always been described that the CB2 receptor is 
preferentially expressed in cells of the immune system (macrophages and microglia), 
neuronal expression of CB2 cannabinoid receptor mRNAs has been recently observed in 
the mouse hippocampus (Li and Kim 2015). It is interesting to note that the function of 
CB2 depends on the cell type where it is expressed. For example, CB2 expression in 
different types of cells in the mature hippocampus plays diverse roles in the regulation of 
memory and anxiety (Li and Kim 2017). It is also expressed in other neuronal 
subpopulations although with a more restricted distribution compared to CB1 receptors 
(Dhopeshwarkar and Mackie 2014a; Hu and Mackie 2015). Our results show a very 
interesting pattern of modulation of CB2 expression: at the neuronal level NRF2 is not 
able to alter the expression of CB2 (Figure 2) suggesting that there must be other 
transcription factors involved. 
Overall, the present work suggests the involvement of NRF2 activity in CB2 
modulation in microglia, and points to NRF2/CB2 as promising pharmacological targets 
for therapeutic strategies to modulate neuroinflammation. 
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FIGURE LEGENDS 
Figure 1: Bioinformatic analysis of putative AREs in the cannabinoid receptor CNR2 
gene promoter. (A) Scheme of the CNR2 gene location at Chr.1p36.11 from the 
Encyclopedia of DNA Elements at UCSC (ENCODE) for the human genome. (B) 
Putative AREs in the CNR2 gene were identified taking as reference the available 
information from ChIP of ARE-binding factors MAFK, MAFF, and BACH1. A MAFK 
binding site was found in a DNase-sensitive and H3K27Ac-rich region upstream the 
CNR2 gene (i.e. most likely promoter region). (C) Table showing the putative ARE 




































































ARE and Core ARE highlighting the main bases involved in NRF2 binding demonstrated 
by (Hirotsu et al. 2012). 
Figure 2: Modulation of NRF2 does not change CB2 expression in neurons. (A) HT22 
cells were incubated in the presence of dimethyl fumarate (DMF) at 20 µM for 4, 8 and 
24 h. Quantitative real-time PCR determination of messenger RNA levels of Cnr2, Nfe2l2 
and NRF2-regulated genes coding Hmox1 and Nqo1, normalized by Tbp (TATA-box 
binding protein) messenger RNA levels. The experiments were performed twice (each 
experiment with n=4). (B) Immunoblot analysis in whole cell lysates of protein levels of 
CB2, NRF2, HO-1, NQO1, and β-ACTIN as a loading control. Representative blots are 
presented. (C) Densitometric quantification of protein levels normalized for β-ACTIN. 
The experiments were performed twice (each experiment with n=2), mean ± SEM. 
Asterisks denote significant differences *p<0.05 **p<0.01 and ***p<0.001, comparing 
the indicated groups with the basal condition according to a one-way ANOVA followed 
by Tukey post-test. (D) Primary culture of rat cortical neurons were incubated in the 
presence of DMF at 20 µM for 4 h. Quantitative real-time PCR determination of 
messenger RNA levels of Cnr2 and Hmox1, normalized by Tbp (TATA-box binding 
protein) messenger RNA levels. Bars indicate n=4, mean ± SEM. (E) HT22 cells were 
transfected with 8 g of pcDNA3.1/V5HisB-mNRF2ΔETGE plasmid or the 
pcDNA3.1/V5HisB, as a negative control. Cells were lysed 24 h after transfection. 
Quantitative real-time PCR determination of messenger RNA levels of Cnr2 and Nfe2l2 
normalized by Tbp messenger RNA levels. (F) HT22 were transduced with lentiviral 
vectors carrying Nfe2l2 shRNA or a control scrambled shRNA. Cells were lysed 7 days 
after infection. The experiments were performed twice (each experiment with n=4, mean 
± SEM). Asterisks denote significant differences *p<0.05 and ****p<0.0001, comparing 




































































Figure 3: NRF2 modulates CB2 expression in microglia. (A) IMG cells were incubated 
in the presence of DMF at 20 µM for 4, 8 and 24 h. Quantitative real-time PCR 
determination of messenger RNA levels of Cnr2, Nfe2l2 and NRF2-regulated genes 
coding Hmox1 and Nqo1, normalized by Tbp messenger RNA levels. The experiments 
were performed twice (each experiment with n=4). (B) Immunoblot analysis in whole cell 
lysates of protein levels of CB2, NRF2, HO-1, NQO1, and β-ACTIN as a loading control. 
Representative blots are presented. (C) Densitometric quantification of protein levels 
normalized for β-ACTIN. The experiments were performed twice (each experiment with 
n=2), mean ± SEM. Asterisks denote significant differences *p<0.05 **p<0.01, 
***p<0.001 and ****p<0.0001, comparing the indicated groups with the basal condition 
according to a one-way ANOVA followed by Tukey post-test. (D) Primary cultures of 
microglia from control wild-type mice (Nfe2l2+/+) and NRF2-knockout mice (Nfe2l2−/−) 
were used. Bars indicate n=4, mean ± SEM. Asterisks denote significant differences 
****p<0.0001, comparing the indicated groups with the control condition according to 
Student's t-test. (E) Differential expression of Cnr2 and Nfe2l2 in the mouse brain 
according to the Brain-RNAseq database (Zhang et al. 2014). Both transcripts are higher 
in microglia; whereas Nfe2l2 levels are lower and Cnr2 levels drop sharply to 
undetectable levels in both neurons and astrocytes. Expression level estimation was 
reported as fragments per kilobase of transcript sequence per million mapped fragments 
(FPKM) value together with confidence intervals for each sample. 
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